A vs. RVTY: Agilent vs. Revvity Stock Comparison
How do Agilent (A) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Agilent (A) and Revvity (RVTY) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | A | RVTY |
|---|---|---|
| Name | AgileThought, Inc. Class A Common Stock | Revvity Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 49.28 billion USD | 17.31 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | November 18, 1999 | February 21, 1973 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | A | RVTY |
|---|---|---|
| Total Return (1Y) | 22.92% | 76.75% |
| Total Return (3Y, Annualized) | 19.33% | 24.22% |
| Total Return (5Y, Annualized) | 3.03% | -1.48% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | A | RVTY |
|---|---|---|
| Volatility (1Y, Annualized) | 33.10% | 40.22% |
| Beta (5Y) | 1.22 | 1.07 |
| Max Drawdown (5Y) | -38.09% | -59.01% |
| Avg. Volume (3M) | 2.25M | 1.89M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | A | RVTY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.56 | 1.80 |
| Sortino Ratio (1Y) | 0.96 | 2.90 |
Profitability
ROE (TTM)
Agilent (A) at 20.97% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for A.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.97%
- Max
- 109.18%
- A
- 20.97%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.45%
- Max
- 109.18%
- Q3
- 6.23%
- RVTY
- 3.45%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Agilent (A) at 19.53% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.53%
- A
- 19.53%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.61%
- Max
- 18.05%
- RVTY
- 8.61%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Agilent (A) at 25.56% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.56%
- Max
- 83.12%
- A
- 25.56%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
17.06%
- Max
- 83.12%
- RVTY
- 17.06%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | A | RVTY |
|---|---|---|
| ROE (TTM) | 20.97% | 3.45% |
| ROA (TTM) | 8.63% | 2.54% |
| Net Margin (TTM) | 19.53% | 8.61% |
| Operating Margin (TTM) | 25.56% | 17.06% |
| Gross Margin (TTM) | 53.65% | 55.91% |
Growth
Revenue Growth
Both Agilent (A) at 6.73% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Agilent (A) at 3.16% and Revvity (RVTY) at -5.91% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | A | RVTY |
|---|---|---|
| Revenue Growth (YoY) | 6.73% | 3.67% |
| Revenue Growth (3Y CAGR) | 0.48% | -4.82% |
| EPS Growth (YoY) | 3.16% | -5.91% |
| EPS Growth (3Y CAGR) | 3.02% | -23.26% |
Financial Strength
Current Ratio (MRQ)
Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Agilent (A) at 2.05 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for A.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.05
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- A
- 2.05
- Min
- 0.10
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.65
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- RVTY
- 2.65
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both Agilent (A) at 0.56 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.56
- Max
- 1.42
- Q3
- 0.65
- A
- 0.56
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- RVTY
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | A | RVTY |
|---|---|---|
| Current Ratio (MRQ) | 2.05 | 2.65 |
| Debt / Equity (MRQ) | 0.56 | 0.38 |
| Net Debt / EBITDA | 1.15 | 2.43 |
Dividends
Dividend Yield (TTM)
Both Agilent (A) at 0.59% and Revvity (RVTY) at 0.19% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.59%
- A
- 0.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.19%
- RVTY
- 0.19%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Both Agilent (A) at 19.98% and Revvity (RVTY) at 13.40% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.98%
- A
- 19.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.40%
- RVTY
- 13.40%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | A | RVTY |
|---|---|---|
| Dividend Yield (TTM) | 0.59% | 0.19% |
| Dividend Payout Ratio (TTM) | 19.98% | 13.40% |
Valuation
P/E Ratio (TTM)
Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.47
- Max
- 85.34
- Q3
- 43.46
- A
- 34.47
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
68.94
- Max
- 85.34
- RVTY
- 68.94
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Agilent (A) at 6.68 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- A
- 6.68
- Q1
- 3.01
- Min
- 0.01
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.88
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- RVTY
- 5.88
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Revvity (RVTY) at 2.39 is valued about in line with its industry on P/B ratio, while Agilent (A) at 6.69 carries an above-peer premium to book — A is pricier on assets.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 13.53
- A
- 6.69
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RVTY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.39
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- RVTY
- 2.39
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | A | RVTY |
|---|---|---|
| P/E Ratio (TTM) | 34.47 | 68.94 |
| P/S Ratio (TTM) | 6.68 | 5.88 |
| P/B Ratio (MRQ) | 6.69 | 2.39 |
| Free Cash Flow Yield (TTM) | 2.15% | 3.62% |